Crossmark

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12885-023-11290-7

Published Online: 2023-08-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ji, Danyang

Luo, Yang

Wang, Jiayu

Chen, Shanshan

Lan, Bo

Ma, Fei

Xu, Binghe

Fan, Ying
Funding

Funding for this research was provided by:

Major project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP, CICAMS-MOMP)
License Information

Text and Data Mining valid from 2023-08-29

Version of Record valid from 2023-08-29
More Information

Article History

Received: 8 March 2023

Accepted: 11 August 2023

First Online: 29 August 2023

Declarations

:

: The authors declare no competing interests.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below